表紙
市場調査レポート

オピオイド誘発性便秘の世界市場:2015〜2019年

Global Opioid-Induced Constipation Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 334065
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
オピオイド誘発性便秘の世界市場:2015〜2019年 Global Opioid-Induced Constipation Market 2015-2019
出版日: 2015年07月01日 ページ情報: 英文 69 Pages
概要

オピオイドは癌以外の慢性疼痛や急性疼痛を患う患者に投与されますが、オピオイド誘発性便秘などをはじめとして胃腸に重大な悪影響を及ぼします。オピオイド誘発性便秘は、標的療法や他のOTC薬の服用とともに生活習慣の改善によって管理することができるものです。世界のオピオイド誘発性便秘市場は、2014〜2019年にかけCAGR30.18%で拡大すると予測されています。

当レポートでは、世界のオピオイド誘発性便秘市場について詳細に分析し、市場の動向と2015〜2019年の成長見通し、作用機序別、投与ルート別、剤形別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 当レポートの範囲

第4章 製品プロファイル

  • Amitiza
  • Movantik/Moventig
  • Relistor

第5章 市場調査方法

第6章 イントロダクション

第7章 疾患の概要

  • オピオイド誘発性便秘の理解
  • 症状
  • 病態生理学
  • 疫学
  • 診断
  • 治療と管理

第8章 パイプラインポートフォリオ

  • パイプライン分子に関する重要情報

第9章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第10章 作用機序別市場セグメンテーション

第11章 投与ルート別市場セグメンテーション

  • 経口
  • 非経口

第12章 剤形別市場セグメンテーション

  • 固形
  • 液状

第13章 地域別セグメンテーション

第14章 購入基準

第15章 市場成長促進因子

第16章 促進因子とその影響

第17章 市場の課題

第18章 促進因子と課題の影響

第19章 市場動向

第20章 動向とその影響

第21章 ベンダー環境

  • 競合シナリオ
  • 市場シェア調査:2014年
  • その他の将来的見込みのあるベンダー

第22章 主要ベンダー調査

  • AstraZeneca plc
  • 武田薬品工業株式会社

第23章 当シリーズの他のレポート

図表

目次
Product Code: IRTNTR6305

About Opioid-induced Constipation

Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.

Technavio's analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.

On the basis of the mechanism of action of drugs, the market is grouped into the following categories:

  • Peripherally Acting Mu-opioid Receptor Antagonist
  • Locally Acting Chloride Channel Activator
  • Others

On the basis of the route of administration of drugs, the market is grouped into the following categories:

  • Oral
  • Parenteral

On the basis of the dosage form of drugs, the market is grouped into the following categories:

  • Solid
  • Liquid

Technavio's report, Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals International

Other Prominent Vendors

  • Abbott
  • Bayer
  • Boehringer Ingelheim
  • C.B. Fleet
  • Cosmo Pharmaceuticals
  • Daewoong
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Ironwood Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Mundipharma
  • Nektar Therapeutics
  • Pfizer
  • Progenics Pharmaceuticals
  • Shionogi
  • SLA Pharma
  • Sucampo
  • Synergy Pharmaceuticals
  • Theravance

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Availability of OTC and Off-label Drugs
  • For a full, detailed list, view our report

Market Trend

  • Shift to Targeted Therapy
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Amitiza
    • 04.1.2. Movantik/Moventig
    • 04.1.3. Relistor

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding Opioid-induced Constipation
  • 07.2. Symptoms
  • 07.3. Pathophysiology
  • 07.4. Epidemiology
  • 07.5. Diagnosis
    • 07.5.1. Patient History
    • 07.5.2. Bristol Stool Form Scale
    • 07.5.3. Physical Examination
    • 07.5.4. Laboratory Tests
    • 07.5.5. Further Investigational Procedures
  • 07.6. Treatment and Management
    • 07.6.1. Pharmacotherapeutic Approach
    • 07.6.2. Non-pharmacotherapeutic Approach

08. Pipeline Portfolio

  • 08.1. Key Information of Pipeline Molecules
    • 08.1.1. Naldemedine
    • 08.1.2. Linaclotide
    • 08.1.3. Axelopran/TD-1211
    • 08.1.4. SP-333
    • 08.1.5. Oral Naloxone

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Mechanism of Action

  • 10.1. Peripherally Acting Mu-opioid Receptor Antagonist
  • 10.2. Locally Acting Chloride Channel Activator
  • 10.3. Others

11. Market Segmentation by Route of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Market Segmentation by Dosage Form

  • 12.1. Solid
  • 12.2. Liquid

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Takeda Pharmaceutical
    • 21.2.2. Valeant Pharmaceuticals International
    • 21.2.3. AstraZeneca
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. AstraZeneca plc
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Business Segmentation by Revenue 2013
    • 22.1.4. Business Segmentation by Revenue 2011-2013
    • 22.1.5. Sales by Geography
    • 22.1.6. Business Strategy
    • 22.1.7. Key Developments
    • 22.1.8. SWOT Analysis
  • 22.2. Takeda Pharmaceuticals
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation by Revenue 2013
    • 22.2.4. Business Segmentation by Revenue 2013
    • 22.2.5. Geographical Segmentation by Revenue 2013
    • 22.2.6. Business Strategy
    • 22.2.7. Recent Developments
    • 22.2.8. SWOT Analysis
  • 22.3. Valeant Pharmaceuticals International
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation by Revenue 2013
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Business Strategy
    • 22.3.7. Key Developments
    • 22.3.8. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Pipeline Drugs: Opioid-induced Constipation
  • Exhibit 3: Snapshot of Global Opioid-induced Constipation Market
  • Exhibit 4: Global Opioid-induced Constipation Market 2014-2019 ($ millions)
  • Exhibit 5: Segmentation of Global Opioid-induced Constipation Market by Mechanism of Action
  • Exhibit 6: Segmentation of Global Opioid-induced Constipation Market by Route of Administration
  • Exhibit 7: Segmentation of Global Opioid-induced Constipation Market by Dosage Form
  • Exhibit 8: Segmentation of Global Opioid-induced Constipation Market by Geography 2014
  • Exhibit 9: Drivers of Global Opioid-induced Constipation Market
  • Exhibit 10: Challenges in the Global Opioid-induced Constipation Market
  • Exhibit 11: Trends of Global Opioid-induced Constipation Market
  • Exhibit 12: Takeda Pharmaceuticals: Key Takeaways
  • Exhibit 13: Valeant Pharmaceuticals International: Key Takeaways
  • Exhibit 14: AstraZeneca: Key Takeaways
  • Exhibit 15: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 16: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 17: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 18: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 19: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 20: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
  • Exhibit 21: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
  • Exhibit 22: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 23: Valeant Pharmaceuticals International: Sales by Geography 2013
Back to Top